BiotechTube
Home/Solu Therapeutics/Michael Boretti, PhD
MB

Michael Boretti, PhD

Chief Business Officer

Solu Therapeutics

Therapeutic Areas

OncologyImmunology & InflammationPain

Solu Therapeutics Pipeline

DrugIndicationPhase
STX-0712Chronic Myelomonocytic Leukemia (CMML)Phase 1
STX-1911Oncology (Novel Targeting)Discovery
STX-0812Inflammatory DiseasePreclinical
STX-0640Systemic Mastocytosis and Immunoderm IndicationsPreclinical
Na ion channel TicTACsPainPreclinical

Leadership Team at Solu Therapeutics

PV
Phil Vickers, PhD
President & CEO
BT
Brandon Turunen, PhD
Co-founder, Chief Scientific Officer
SS
Sergio Santillana, MD, MSc, MBA
Chief Medical Officer
CW
Christoph Westphal, MD, PhD
Co-founder, Chairperson of the Board
View full Solu Therapeutics profile